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Background: Glycoconjugated vaccines composed of polysaccharide antigens covalently linked to immunogenic
carrier proteins have proved to belong to the most effective and safest vaccines for combating bacterial pathogens.
The functional transfer of the N-glycosylation machinery from Campylobacter jejuni to the standard prokaryotic host
Escherichia coli established a novel bioconjugation methodology termed bacterial glycoengineering.
Results: In this study, we report on the production of a new recombinant glycoconjugate vaccine against Shigella
flexneri 2a representing the major serotype for global outbreaks of shigellosis. We demonstrate that S. flexneri 2a
O-polysaccharides can be transferred to a detoxified variant of Pseudomonas aeruginosa carrier protein exotoxin A
(EPA) by the C. jejuni oligosaccharyltransferase PglB, resulting in glycosylated EPA-2a. Moreover, we optimized the
in vivo production of this novel vaccine by identification and quantitative analysis of critical process parameters for
glycoprotein synthesis. It was found that sequential induction of oligosaccharyltransferase PglB and carrier protein
EPA increased the specific productivity of EPA-2a by a factor of 1.6. Furthermore, by the addition of 10 g/L of the
monosaccharide N-acetylglucosamine during induction, glycoconjugate vaccine yield was boosted up to 3.1-fold.
The optimum concentration of Mg2+ ions for N-glycan transfer was determined to be 10 mM. Finally, optimized
parameters were transferred to high cell density cultures with a 46-fold increase of overall yield of glycoconjugate
compared to the one in initial shake flask production.
Conclusion: The present study is the first attempt to identify stimulating parameters for improved productivity of
S. flexneri 2a bioconjugates. Optimization of glycosylation efficiency will ultimately foster the transfer of lab-scale
expression to a cost-effective in vivo production process for a glycoconjugate vaccine against S. flexneri 2a in E. coli.
This study is an important step towards this goal and provides a starting point for further optimization studies.
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Gram-negative, non-motile, enteroinvasive Shigella bac-
teria are human pathogens that cause severe infection
known as shigellosis. The disease is estimated to affect
165 million people annually, leading to approximately
1.1 million deaths per year (WHO). Especially children
under the age of five living in environments with poor
sanitation and hygiene conditions bear an elevated risk
to contract an infection [1,2]. Among the different Shigella
serotypes S. flexneri 2a is the most widespread strain
worldwide and responsible for most endemic outbreaks in
developing countries [3].
Vaccination has been proven as a powerful strategy to
combat infectious diseases like shigellosis. In the last
years several different approaches have been developed
to combat S. flexneri 2a, including vaccination with at-
tenuated or heat-killed S. flexneri 2a strains [4,5], recom-
binant outer membrane proteins [6,7], subunit-based
vaccines [8] and glycoconjugate vaccines [9]. Particularly,
conjugated vaccines composed of O-polysaccharide units
of the lipopolysaccharide (LPS) covalently linked to im-
munogenic carrier proteins have attracted remarkable at-
tention due to their inherent ability to evoke a T-cell
dependent, long-lasting, serotype specific protective im-
munity. In contrary polysaccharide-only vaccines are
often poor immunogens and elicit only T-cell independ-
ent, short-lived and low-affinity antibody responses
[10,11]. It has already been demonstrated that glycocon-
jugates comprising O-specific polysaccharides of S. flex-
neri 2a covalently bound to Pseudomonas aeruginosa
exoprotein A (EPA) are safe, immunogenic and effica-
cious in clinical phase III studies [12]. However, broad
applicability of glycoconjugated vaccines has been hin-
dered by the complex production process which relies
either on sophisticated chemical synthesis to obtain, ac-
tivate and couple the oligosaccharide to the carrier pro-
tein [9] or on cultivation of the bacterial pathogen in
large cultures to obtain the desired O-specific polysac-
charides which constitutes a major health and safety
issue. Furthermore, processing of the chemical conju-
gates is laborious and requires different purification
steps accompanied by substantial loss of target material,
resulting in a low efficiency and cost-effectiveness [13].
Moreover, chemical crosslinking is highly unspecific,
leading to low robustness and reproducibility of the pro-
duction and consequently to difficulties in quality con-
trol of the vaccine.
Basic research of bacterial N-glycosylation resulted in
the seminal discovery of the functional transfer of the
Campylobacter jejuni N-glycosylation machinery in the
standard prokaryotic host E. coli [14]. Key enzyme of
this recombinant technology is the C. jejuni oligosac-
charyltransferase PglB. It exhibits relaxed substrate spe-
cificity towards glycans from different origins [15] and isable to link these polysaccharides covalently to target
proteins (e.g. immunogenic carrier proteins) that contain
specific N-glycosylation sites [16]. Thereby tailor-made
glycoconjugate vaccine candidates can be produced in
non-toxic, engineered E. coli and purified in a simplified
process from the bacterial periplasm as demonstrated re-
cently for several polysaccharides of pathogens [17-20].
Depending on the polysaccharide substrate, there is a
need for improving the glycosylation efficiency. Often a
high percentage of the target protein remains unglycosy-
lated, i.e., the glycoconjugate represents a small portion
of the totally produced recombinant protein. A few stud-
ies describe the optimization of glycosylation efficiency
by manipulation of the cellular metabolism [21-23].
In order to produce a more cost-effective vaccine for
vaccination campaigns in developing countries, glyco-
conjugate yields can be optimized with respect to spe-
cific and volumetric productivity. High cell density
cultivation (HCDC) of recombinant E. coli is a major
strategy for maximizing volumetric productivity of re-
combinant proteins [24,25]. High cell densities can be
reached by fed-batch cultivation, thereby reducing cul-
ture volume, enhancing biomass production and product
recovery and hence reducing costs significantly. So far
only one report describing a fed-batch bioprocess for
in vivo production of a glycoconjugate vaccine against S.
dysenteriae O1 in E. coli has been published [18].
In this study we report on (i) the establishment of an
in vivo production system for the expression of a glyco-
conjugate vaccine against S. flexneri 2a in E. coli, (ii) the
identification of critical parameters and cultivation con-
ditions influencing the in vivo glycosylation efficiency
and finally (iii) the transfer of the identified conditions
to high cell density cultivations under controlled condi-
tions to increase overall glycoconjugate yield. By applying
a fed-batch process with the identified and optimized pa-
rameters the glycoconjugate yield was increased 46-fold
compared to the shake flask cultures under non-optimized
conditions.
Results
In vivo glycosylation of EPA with S. flexneri 2a
O-polysaccharides
In vivo glycosylation of immunogenic carrier proteins
with O-polysaccharides of bacterial pathogens in genet-
ically engineered E. coli have been demonstrated to be a
promising synthesis route for the production of glycocon-
jugate vaccines [17-20,26]. Due to the relaxed substrate
specificity of the C. jejuni oligosaccharyltransferase PglB,
various O-polysaccharides (O-PS) from Gram-negative
and Gram-positive bacteria were successfully transferred
to carrier proteins. We aimed at extending this palette of
potential vaccines by producing a glycoconjugate against
Shigella flexneri 2a, one of the most clinically relevant
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neered harboring the O-antigen cluster of S. flexneri 2a
integrated on its genome under control of its native,
constitutive promoter and thereby replacing the en-
dogenous wb cluster. Among other genetic modifica-
tions (see Materials and methods section) this strain
lacks the O-antigen ligase waaL, thus preventing
O-antigen transfer to the lipid A core, thereby promoting
PglB-mediated transfer of the O-PS to the desired carrier
protein. By co-expression of PglB under control of the
IPTG-inducible Ptac promoter with a detoxified version of
Pseudomonas aeruginosa exotoxin A (EPA) engineered
with two N-glycosylation sites and an E. coli DsbA signal
sequence for export to the periplasm, the S. flexneri 2a
O-polysaccharides are supposed to be transferred to the
respective sites of the carrier protein. As negative control,
PglB was replaced by an inactive variant referred to as
PglBmut (W458A and D459A). After extraction of the
periplasmatic fraction of induced E. coli cells, Western
blot analysis either with anti-EPA antibody (Figure 1A)Figure 1 In vivo glycosylation of EPA with Shigella flexneri 2a O-polys
carrier protein and either PglB or PglBmut were grown in shake flasks at 30°
uninduced. 24 h post induction OD600-normalized periplasmic extracts wer
B) anti-2a antibody (B: right panel overexposed Western blot). C) Periplasm
enzyme-linked immunosorbent assay (ELISA). Error bars represent the standor with anti-S. flexneri 2a antibody (Figure 1B) was per-
formed. A dominant band at 70 kDa was detected after
hybridization with anti-EPA antibody in lane 1 and 3
(Figure 1A), representing the unglycosylated EPA carrier
protein. A ladder of bands with higher molecular mass
between 100–130 kDa was additionally and exclusively
detected in lane 1 and constitutes glycosylated EPA pro-
tein with polysaccharide chains of different length gener-
ated by the coordinated action of the enzymes Wzy and
Wzz. Wzy is responsible for polymerization of the O-PS
and Wzz determines the extent of polymerization. In the
uninduced sample in lane 2 only a very faint band at
70 kDa arising from leaky EPA expression from the ParaBAD
promoter was visible. To elucidate whether also a specific
antibody against S. flexneri 2a reacts with the proposed
glycoprotein, Western blots of periplasmic extracts were
hybridized with anti-2a antibody. The ladder of bands of
high molecular mass was also detected with this specific
antibody (lane 1, Figure 1B) while no glycoprotein was
detected in the PglBmut and uninduced samples. Thisaccharides. E. coli expressing Shigella flexneri 2a polysaccharides, EPA
C and induced with 1 mM IPTG and 2 g/L arabinose or retained
e prepared and analyzed by Western blot with A) anti-EPA antibody or
ic extracts from A) and B) were analyzed and quantified by sandwich
ard deviations of three biological replicates.
Figure 2 Time course of in vivo glycosylation. EPA-2a producing
E. coli cells were cultivated at 30°C in shake flasks (A) or in a 1
L-bioreactor (B and C). Samples were taken periodically after induction
with 1 mM IPTG and 2 g/L arabinose followed by preparation of
OD600-normalized periplasmic extracts and analysis by sandwich ELISA
(A and B) or Western blot with anti-EPA antibody (C).
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is responsible and necessary for glycoprotein synthesis.
Distinct bands below 70 kDa were also visible (Figure 1B,
left and right overexposed panel, lanes 1, 2 and 3) and
most likely represent undecaprenyl pyrophosphate (UPP)-
linked O-antigens or degradation products. Although Shi-
gella flexneri 2a O-PS were successfully transferred to
EPA, most of the carrier protein remained unglycosylated
(Figure 1A). Hence, a primary target of this study was to
identify parameters and factors improving the yield of S.
flexneri 2a glycoconjugates.
Development of a reliable assay for quantification of
glycoprotein
A prerequisite for optimization of glycoprotein yield is the
availability of a reliable quantification method. In Figure 1A
and 1B it was demonstrated that anti-EPA and anti-2a anti-
bodies recognize EPA carrier and O-antigens, respectively.
Therefore, we developed a sandwich enzyme-linked
immunosorbent assay (ELISA) by coating high affinity
96-well plates with anti-EPA antibody as capture antibody
and detecting bound glycoproteins from periplasmic frac-
tions with anti-2a antibody (detection antibody). Appropri-
ate dilutions of periplasmic extracts and antibody solutions
were crucial to obtain high signal-to-noise ratios. Periplas-
mic samples from Figure 1A and Figure 1B were applied to
the described ELISA format. The glycoprotein-containing
sample resulted in a high readout at 450 nm while only
negligible background signals were detected for the unin-
duced and PglBmut samples, thus reflecting the Western
blot results accurately (Figure 1C). With the described
ELISA configuration the relative yield of EPA-2a in
periplasmic extracts obtained from different cultivation
conditions could be easily compared on the same
ELISA plate. However, absolute quantification is chal-
lenging because unglycosylated EPA is competing with
EPA-2a for capture antibody binding sites. Hence, puri-
fied EPA-2a does not represent an appropriate standard
for this approach.
Kinetics of EPA-2a production in shake flask and
bioreactor
After establishment of the quantification method for
EPA-2a, the time course of in vivo glycosylation was
monitored to obtain information about the optimal
induction period at shake flask and bioreactor scale.
Samples were taken periodically post induction and
glycoprotein content was analyzed by ELISA after ex-
traction. For both scales, specific productivity (i.e. glyco-
protein content per cell) increased from 0 to 24 h with a
maximum at 24 h (Figure 2A and 2B). Western blot
analysis of bioreactor samples confirmed this result
(Figure 2C). Since both profiles (Figure 2A and B) depict
a similar progression of glycosylation per cell, the time-dependent production of EPA-2a glycoconjugates can be
transferred directly from shake flask to bioreactor scale.
In all following experiments engineered E. coli were in-
duced for 24 h for EPA-2a production.
Induction strategy affects product yield
The oligosaccharyltransferase PglB is under control of
the IPTG-inducible Ptac promoter while the carrier pro-
tein EPA is controlled by the ParaBAD promoter and its
expression can be initiated by the addition of arabinose.
This setup provides the opportunity to start expression
of the two proteins at different time points. We therefore
Figure 3 Impact of order of induction on EPA-2a yield. For
EPA-2a production engineered E. coli were incubated at 30°C in
shake flasks, and PglB and EPA carrier protein were induced either
simultaneously (0 h) with 1 mM IPTG and 2 g/L arabinose, respectively,
or EPA was induced at indicated time points after PglB induction.
OD600-normalized periplasmic extracts were prepared 24 h post
induction and analyzed by sandwich ELISA. Error bars represent the
standard deviations of three biological replicates.
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on the specific productivity of EPA-2a by inducing PglB
and EPA, either simultaneously or sequentially (first EPA,
then PglB or vice versa). While inducing EPA 2 h before
initiating PglB expression resulted in similar yield of glyco-
protein compared to the simultaneously induced samples
(Table 1), the sequential strategy with induction of PglB
expression 2 h prior to that of EPA yielded a 1.6-fold in-
crease of glycoconjugates (Figure 3 and Table 1). We fur-
ther investigated different intervals from 0 to 2 h between
both inducer pulses and found that glycoconjugate yield
increased from simultaneous induction (0 h) to 0.5 h and
reached a plateau at ≥1 h (Figure 3). The sequential in-
duction did not lead to any significant change in the
OD600 reached compared to simultaneous induction (data
not shown). Thus, we conclude that a sequential induc-
tion strategy is advantageous for glycosylation efficiency
and increases the specific yield of EPA-2a significantly
(1.6-fold).
N-acetylglucosamine stimulates glycosylation efficiency
Serological classification of Shigella serotypes is based on
the nature of the repeating unit (RU) of the O-specific
polysaccharide moiety of the outer lipopolysaccharide
layer (LPS), which acts as a major virulence factor for
Shigella [27] and is the main target of the host adaptive
immunity. The repeating unit of S. flexneri 2a is composed
of a D-N-acetylglucosamine (D-GlcNAc) at the reducing
end and three consecutive L-rhamnose (L-Rha) residues.
This specific polysaccharide sequence motivated us to
examine whether supplementation of the culture broth
with monosaccharides occurring on the polysaccharide
(D-GlcNAc, L-rhamnose) can stimulate glycoprotein syn-
thesis. While addition of L-rhamnose exhibited only a
marginal effect on the yield of EPA-2a (data not shown),
D-GlcNAc increased the specific yield of glycosylated pro-
tein considerably. Analysis of OD600-normalized periplas-
mic extracts revealed that the amount of glycoconjugate
per cell was improved 2-fold by the addition of 4 g/L D-
GlcNAc compared to the sample without D-GlcNAc
addition (Figure 4A). Since overexpression of recombinant
proteins and particularly membrane proteins like PglB are
considered to cause high stress to E. coli cells [28,29] and
numerous publications pointed out that the disaccharideTable 1 Induction strategies and influence on EPA-2a yield
Order of induction Specific EPA-2a yield (A450 nm/OD600)
Simultaneous 0.63
Sequential (1. EPA 2. PglB) 0.55
Sequential (1. PglB 2. EPA) 1.0
EPA-2a expressing cells were incubated at 30°C. Cultures were induced either
simultaneously with 1 mM IPTG and 2 g/L arabinose, or EPA was induced 2 h
prior to PglB (1. EPA 2. PglB) or vice versa by the addition of 1 mM IPTG and
2 g/L arabinose. Values were obtained based on OD600-normalized
periplasmic extracts.trehalose is synthesized as a stress-responsive factor
[30-32], we investigated if supplementation of the cul-
ture medium with trehalose is also advantageous for
EPA-2a synthesis. However, no significant effect on
glycoprotein yield could be detected after trehalose
addition (data not shown). To examine the specific ef-
fect of N-acetylglucosamine in more detail, a dose–
response curve with different amounts of D-GlcNAc
was recorded in 96-deep well plates. An increase of
N-acetylglucosamine concentration led to improved
specific productivity of EPA-2a up to 3.1-fold with
10 g/L GlcNAc (Figure 4B). This improved production of
EPA-2a was not due to any effect of GlcNAc on the bio-
mass as shown in Figure 4C, thereby confirming the spe-
cific, stimulating effect of N-acetylglucosamine for EPA-2a
formation.
Involvement of Mg2+ ions on glycoprotein synthesis
The transfer of O-PS to the desired target protein is me-
diated by the oligosaccharyltransferase PglB thereby
forming an N-glycosidic linkage between the amide ni-
trogen of the acceptor asparagine and a distinct carbon
of the monosaccharide at the reducing end of the poly-
saccharide chain. The precise reaction mechanism is not
understood. However, it has been demonstrated that
PglB and other oligosaccharyltransferases require diva-
lent cations like Mn2+ or Mg2+ for activity [33,34]. Three
acidic amino acids (D56, D154 and E149) in the catalytic
pocket coordinate the binding of a total of three divalent
cations. Mutations of these residues resulted in a de-
crease of glycosylation efficiency of > 50% [35]. Therefore,
glycosylation efficiency of EPA with S. flexneri 2a O-PS
Figure 4 Effect of N-acetylglucosamine on glycoconjugate
synthesis. A) Comparison of specific EPA-2a yield in the absence (−)
or presence (+N-Ac) of N-acetylglucosamine (4 g/L) during simultaneous
induction of PglB and EPA in shake flasks. B) EPA-2a expression in the
presence of increasing amounts of N-acetylglucosamine (0 g/L – 10 g/L)
in 96-deep well plates. Values were divided by the corresponding final
OD600 before normalization to exclude that the beneficial effect of
N-acetylglucosamine is only due to increase of biomass formation. E. coli
cells were incubated at 30°C, and PglB and EPA were induced
simultaneously for 24 h by addition of 1 mM IPTG and 2 g/L arabinose,
respectively. C). The final OD600 values in the presence of increasing
amounts of N-acetylglucosamine (0 g/L – 10 g/L) in 96-deep well plates.
Error bars represent the standard deviations of three biological replicates.
Figure 5 Mg2+ stimulates EPA-2a expression. A) Culture medium
was supplemented with different amounts of Mg2+, and EPA-2a was
quantified in OD600-normalized periplasmic extracts by ELISA after
incubation at 30°C and simultaneous induction with 1 mM IPTG and
2 g/L arabinose for 24 h in 96-deep well plates. B) Influence of
different amounts of Mg2+ on the final OD600 values i in 96-deep
well plates. Error bars represent the standard deviations of three
biological replicates.
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trations. An increase of Mg2+ ions in the range from 0 to
10 mM resulted in elevated glycoconjugate levels with an
optimum of a MgSO4 concentration at 10 mM (Figure 5A).
Mg2+ ions in the range from 0 to 10 mM did not lead to
any significant change in biomass reflexed by OD600 values(Figure 5B). In the presence of higher MgSO4 concentra-
tions (20 and 50 mM) a decrease in product yield was ob-
served. These results demonstrate the promoting effect of
Mg2+ on EPA-2a formation up to 10 mM.
Synergistic effect of sequential induction and addition of
N-acetylglucosamine
After identification of critical parameters e.g. the order
of induction, the addition of N-acetylglucosamine and
the presence of Mg2+ ions, the combined effect of opti-
mized conditions was evaluated in shake flasks. Simul-
taneous induction of PglB and EPA carrier without
addition of N-acetylglucosamine was used as the non-
optimized conditions. Sequential induction of both pro-
teins with a gap of 2 h between the inducer additions
increased the yield 1.7-fold. The highest yield was ob-
tained when the required proteins were induced sequen-
tially and 10 g/L N-acetylglucosamine was added
concomitantly to the culture broth, leading to a 2.6-fold
increase of glycoconjugate yield compared to the non-
optimized condition. The economical feasibility of the
glycoconjugate production processes depends both on
the attainment of high cell density and high levels of
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vaccines against S. flexneri 2a in sufficient amounts for
immunization campaigns, the conditions optimized in
this study were finally applied to high cell density cul-
tures. EPA-2a producing cells were grown at 30°C until
the optical density reached an OD600 value of 9. At this
time 1 mM IPTG and 10 g/L N-acetylglucosamine were
added to the culture. 2 h later the carrier protein EPA
was induced by addition of 2 g/L arabinose, and feed
medium was applied with a constant rate of 7.8 ml/h to
provide the cells with required nutrients. Table 2 sum-
marizes and compares directly the results from non-
optimized and optimized shake flask experiments with
bioreactor fermentations. While simultaneously induced
shake flask cultures without N-acetylglucosamine reached
a final OD600 of 1.9, sequential induction and the addition
of 10 g/L N-acetylglucosamine led to an OD600 of 2.6 in
shaken cultures and to an OD600 of 41.1 in fed-batch fer-
mentations after 24 h of induction. The specific yield of
optimized conditions determined by ELISA increased 2.6-
fold in shake flasks and 2.1-fold in fed-batch cultivations,
respectively. The obtained high cell density led to an in-
crease of volumetric productivity by a factor of 46.2 com-
pared to the non-optimized shake flask condition, while
optimized conditions resulted in an increase of volumetric
productivity by a factor of 3.6 in shake flask. The specific
productivity was slightly decreased from a A450 value of
1.00 to 0.82 when optimized shake flask cultures were dir-
ectly compared to high cell density fermentations, an ef-
fect which has also been observed previously [36].
Discussion
Bacterial glycoengineering enables the in vivo glycosyl-
ation of immunogenic carrier proteins with bacterial
O-polysaccharides, thus providing a novel platform for
the production of tailor-made glycoproteins as safe and ef-
fective vaccines against various pathogens. Thereby the ex-
pensive and sophisticated chemical synthesis and coupling
process is circumvented and cost-effective vaccines for
immunization campaigns for developing countries can be
realized. The most widely used enzyme technology ex-
ploits the relaxed substrate specificity of the Campylobac-
ter jejuni oligosaccharyltransferase PglB towards diverse
lipid-linked polysaccharides [15,37,38]. The PglB system
was recently applied to produce glycoconjugate vaccines









Shake flask Simultaneous - 0.8
Shake flask Sequential 10 0.8
Bioreactor fed-batch Sequential 10 9.1
*Values were obtained based on OD600-normalized periplasmic extracts.tularensis and Brucella abortus [17-20,39]. In this study
we report the bioconjugation of S. flexneri 2a polysaccha-
rides to the well-established immunogenic carrier exotox-
oid A of P. aeruginosa (EPA). The S. flexneri 2a repeating
unit consists of three rhamnose residues and a GlcNAc at
the reducing end, similarly to other Shigella and E. coli
serotypes, e.g. S. dysenteriae type 1 and E. coli O7 oligo-
saccharide [40,41]. We could show that S. flexneri 2a
O-polysaccharides are a substrate for PglB-mediated
transfer to EPA and that the resulting glycoproteins were
recognized by a specific antibody targeting S. flexneri 2a
glycans. After establishing the S. flexneri 2a system, our
study aimed at identifying critical parameters stimulating
glycoconjugate yield. Analysis of samples at different time
points post induction showed that maximum glycoconju-
gate yield per cell was obtained after 24 h, even though
high amounts of EPA carrier protein were already present
in the periplasm 1 h after induction. A similar observation
was made when EPA-Shigella O1 glycoconjugates were
produced in E. coli [18]. This leads to the assumption that
either PglB activity, O-polysaccharide assembly or polysac-
charide precursor supply is rate-limiting. Induction time
point and induction period plays a pivotal role in the ex-
pression of many recombinant proteins and the effective-
ness of bioprocesses [42-44]. Upon addition of the
inducer, overexpression of recombinant proteins con-
sumes high amounts of essential biosynthetic precursors
(e.g. amino acids, nucleotides). Thereby the cellular me-
tabolism is negatively influenced which finally leads to
multiple stress responses, reduced biomass formation and
in turn to impaired recombinant protein expression
[45-48]. Using the here described enzymatic protein gly-
can coupling technology, the situation is even more severe
compared to the overexpression of single recombinant
proteins. In this case, numerous components, i.e. oligosac-
charyltransferase PglB, periplasmic protein carrier EPA
and a whole set of enzymes required for lipid-linked
O-polysaccharide synthesis have to be functionally
expressed in a coordinate manner to enable maximum
yield of the glycoconjugates. In the S. flexneri 2a system,
the glycosyltransferase cluster was integrated in the host
genome and constitutively expressed from its natural pro-
moter. However, PglB oligosaccharyltransferase and EPA
carrier protein were under control of the Ptac and ParaBAD
promoters and were induced by IPTG and L-arabinose,
respectively. The beneficial effect of sequential inductionin shake flask and high cell density cultivations






1.9 0.38 0.72 -
2.6 1.00 2.6 3.6
41.1 0.82 33.7 46.2
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is probably related to the temporal separation of the over-
expression of both components. This might relax the
metabolic burden to some extent and allow a functional
integration of PglB with its 13 transmembrane helices into
the cell membrane by the precise interplay of translocases
and insertases [49]. A correctly inserted, functional PglB,
which is already present at induction of carrier protein ex-
pression, presumably is able to better transfer Shigella
flexneri 2a glycans to EPA during export of the carrier
polypeptide to the periplasm, possibly before folding. In
the case of simultaneous or opposite induction, a larger
portion of EPA remains unglycosylated due to the absence
of functional PglB immediately after induction.
We have shown in this study that the addition of
N-acetylglucosamine increased the yield of EPA-2a sig-
nificantly. N-acetylglucosamine (GlcNAc) is an acetylated
glucosamine derivative and plays a key role at the bacterial
cell surface. Besides, it is also an important signaling mol-
ecule [50]. The first step in Shigella flexneri 2a O-
polysaccharide assembly is the addition of one GlcNAc
residue from the nucleotide activated sugar donor UDP-
GlcNAc to the membrane-bound undecaprenyl pyrophos-
phate [51,52]. The UDP-GlcNAc is de novo synthesized in
E. coli by the conversion of fructose-6-phosphate to
glucosamine-6-phosphate [53], which is further processed
by a glucosamine mutase to glucosamine-1-phosphate
[54]. Acetylation of the latter intermediate leads to forma-
tion of GlcNAc-1-phosphate, which is the substrate for
the final uridyl transfer generating UDP-GlcNAc [55]. It is
assumed that synthesis of glucosamine-6-phosphate is
the rate limiting step in UDP-GlcNAc synthesis [56]. In
contrast to eukaryotic cells, bacteria are not able to
synthesize GlcNAc-6-phosphate. However, when N-
acetylglucosamine is present in the culture medium, the
N-acetylglucosamine transporter NagE in the inner
membrane of E. coli imports GlcNAc to the cytosol
where it is immediately phosphorylated by the phospho-
transferase system (PTS) to form GlcNAc-6-phosphate
[57]. GlcNAc-6-phosphate is then converted via mul-
tiple enzymatic steps to GlcNAc-1-phosphate, which is
finally activated by UTP to UDP-GlcNAc. Hence, the
rate-limiting step of the de novo synthesis of glucosamine-
6-phosphate is circumvented, which might result in an
increased pool of the cytosolic activated sugar donor
UDP-GlcNAc for glycan assembly and thus increase
glycoprotein production. This hypothesis is supported
by a recently published study, aiming at identifying
genes beneficial for in vivo glycosylation of C. jejuni
AcrA in a genome wide screen [21]. Among five other
identified genes, the bi-functional enzyme Dxs, an
UDP-N-acetylglucosamine pyrophosphorylase/glucosa-
mine-1-phosphatase involved in UDP-GlcNAc precursor
synthesis was identified and led to 1.6 fold increased AcrAglycosylation [21]. Interestingly, if GlcNAc was added to
mammalian cells exogenously, it was also converted to
UDP-GlcNAc, increasing the intracellular UDP-GlcNAc
pool. The elevated level of UDP-GlcNAc is believed to re-
sult in enhanced N-glycan branching of glycosylated pro-
teins in the Golgi apparatus [58].
In addition to the stimulating effect of N-acetylgluco-
samine, we found that Mg2+ ions are able to promote
EPA-2a synthesis. Maximum EPA-2a yield was achieved
by supplementation of the culture medium with 10 mM
MgSO4. Divalent metal ions like Mg
2+ and Mn2+ are es-
sential co-factors for enzymatic reactions catalyzing the
formation of phosphodiester bonds. The first reaction of
the S. flexneri 2a O-polysaccharide assembly, the transfer
of the GlcNAc moiety from UDP-GlcNAc to undecapre-
nyl pyrophosphate, is catalyzed by the integral mem-
brane protein WecA in E. coli. In vitro assays with crude
membrane extracts from overexpressing wecA E. coli
cells demonstrated the absolute requirement of Mg2+
ions for the GlcNAc transfer [51]. Purified WecA from
T. maritima revealed a Mg2+ -dependent activity profile
with a maximum at 10 mM and inhibitory effects with
higher Mg2+ concentrations similar to our data [59].
However, in contrast to the in vitro assay, EPA-2a was
also produced in the absence of additional Mg2+ ions.
This might be due to the complex medium components,
yeast extract and soy peptone, in the culture medium
which contain considerable amounts of metal ions. Ac-
cording to Liu et al. [60], the two glycosyltransferases
WbgF and WbgG define the specific sequence of the re-
peating unit of the S. flexneri 2a O-polysaccharide by
sequential addition of three rhamnose residues. The
donor substrate for these glycosyltransferases is dTDP-
rhamnose. Detailed biochemical characterization of
WbgF and WbgG is lacking, so the requirement of diva-
lent cations for their acitivity is speculative. The same
holds true for GtrII, a glucosyltransferase attaching a
glucose residue to rhamnose III, converting the repeat-
ing unit of S. flexneri serotype Y in 2a [61]. There is a
general agreement that metal ions are required for oli-
gosaccharyltransferase activity in different organisms
[34,62,63]. A recent study on PglB from Campylobacter
lari demonstrated the requirement of either Mn2+ or
Mg2+ for DQNAT sequon binding of acceptor peptides
[33]. It was shown that Mn2+ binds the acceptor with
higher affinity than Mg2+, but this does not necessarily
correlate with higher oligosaccharyltransferase catalytic
activity. When essential amino acids (Asp-56 and Glu-
319) involved in metal ion binding were mutated, glyco-
sylation efficiency decreased dramatically and a double
mutant was completely inactive [35]. Although Mn2+ is
supposed to be the physiological cation for PglB, we
performed our experiments in the presence of different
MgSO4 which is an essential component of the production
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EPA-2a yield in the presence of 10 mM MgSO4 might be
generated by an overlapping effect of increased activity of
involved glycosyltransferases (WecA, WbgF, WbgG) for
O-polysaccharide assembly and enhanced catalytic activity
of the oligosaccharyltransferase PglB. It would now be in-
teresting to test whether the addition of extra Mn2+ also
has a beneficial effect.
Conclusion
The present study is the first attempt to identify stimu-
lating parameters for improved productivity of S. flexneri
2a bioconjugates. Three major factors were identified
and quantitatively analyzed. A sequential induction strat-
egy with a 2 hour gap between both inducer pulses, the
addition of 10 g/L N-acetylglucosamine and the pres-
ence of 10 mM MgSO4 were favorable for EPA-2a
production. By applying these parameters to high cell
density cultures, EPA-2a yield was increased 46-fold
compared to initial shake flask conditions. It is likely
that these factors are not S. flexneri 2a specific but en-
able increased productivities also of other glycoconju-
gates with similar structural features, i.e. a GlcNAc
residue at the reducing end. However, this needs to be
analyzed in further studies. Optimization of glycosylation
efficiency will ultimately foster the transfer of lab-scale
expression to a cost-effective and reasonable in vivo pro-
duction process for a glycoconjugate vaccine against S.
flexneri 2a in E. coli. This study is an important step to-
wards this goal and provides a starting point for further
optimization studies.
Materials and methods
Bacterial strains and plasmids
E. coli 1052 (W3110, F−, IN(rrnD-rrnE)1, rph1, Δwbbl,
ΔwbbJ, ΔwbbK, gtrS::gtrII, ΔwaaL, wb cluster::O-antigen
cluster of S. flexneri 2457 T, araBAD::cat) (provided by
GlycoVaxyn AG, Schlieren, Switzerland) harboring the
O-antigen cluster of S. flexneri 2a under control of its
native (constitutive) promoter on the genome was used
as the production strain for all in vivo glycosylation experi-
ments in this study. This strain also carries a genomic in-
tegration of the gene encoding glucosyltransferase GtrII,
which attaches a glucose branch to the middle rhamnose
residues essential for proper immune response, at the gtrS
locus. The oligosaccharyltransferase PglB from C. jejuni
was expressed from a spectinomycin-selectable, low-copy
number expression plasmid (backbone pEXT21 [65], ori-
gin of replication IncW) under control of the IPTG-
inducible hybrid promoter Ptac. The PglB sequence was
codon-optimized for expression in E. coli by gene syn-
thesis (GenScript, Piscataway, NJ, USA). A glycosylation
deficient PglB variant (PglBmut) harboring two point mu-
tations (W458A and D459A) was used as negativecontrol. For Western blot detection a hemagglutinin oligo-
peptide tag (HA) was genetically fused to the C-terminal
end of the corresponding PglB sequences. As carrier pro-
tein, a detoxified version of P. aeruginosa exotoxin A
(EPA, L552V, ΔE553) containing two engineered N-
glycosylation sites (N262 and N398) was expressed from
an ampicillin-resistant, high-copy number plasmid under
control of the arabinose-inducible promoter ParaBAD
(pEC415 [39]). For Sec-dependent secretion to the peri-
plasm a DsbA signal peptide was genetically fused at the
N-teminal end of EPA.
Expression of EPA-2a in shake flasks
Small scale recombinant expression of the glycoconjugate
vaccine EPA-2a was performed in 100 ml Erlenmeyer
flasks (without baffles) filled with 50 ml medium. The
complex medium used in this study was composed of
10 g/L yeast extract (Bacto yeast extract, BD, Le Pont de
Claix, France), 20 g/L soy peptone (soy peptone A3 SC,
Organotechnie, La Courneuve, France), 9 g/L KH2PO4,
5 g/L (NH4)2SO4, 1 g/L citric acid, 4 g/L glycerol, 10 mM
MgSO4 and 10 ml/L trace element solution (10 g/L
CaCo3, 20 g/L FeCl3*6 H2O, 1.5 g/L MnCl2*4 H2O, 0.3 g/
L H3BO3, 0.25 g/L CoCl2*6 H2O, 0.15 g/L CuSO4, 0.5 g/L
ZnCl2, 2 g/L NaMoO4, 84.4 g/L Na4EDTA*2 H2O, 20 ml/
L, 37% HCl). To maintain plasmid stability the medium
was supplemented with 100 μg/ml ampicillin and 80 μg/
ml spectinomycin. Shake flasks were inoculated from
overnight tube cultures to a starting OD600 value of 0.08
and incubated at 30°C and 160 rpm until cultures reached
an OD600 of 0.6 – 0.8. PglB expression was induced by the
addition of 1 mM IPTG, and the protein carrier EPA was
induced by the addition of 2 g/L arabinose. For sequential
induction, IPTG was added at an OD600 of 0.6 – 0.8 and
2 h later 2 g/L arabinose was added (if not stated other-
wise). N-acetylglucosamine was always added concomi-
tantly with IPTG. Induced bacteria cells were incubated
over night before harvesting by centrifugation (6500 × g,
5 min, 4°C).
Cultivation in 96-deep well plates
For screening of parameters that influence EPA-2a pro-
duction, recombinant E. coli cells were grown in 96-
deep well plates (DWPs) (VWR, order No. 732–0585) in
1.6 ml of the same medium used for shake flask cultures.
DWPs were inoculated with an uninduced overnight
shake flask culture to a starting OD600 of 0.05 – 0.1 and
incubated at 30°C and 500 rpm in a specialized micro-
plate incubator (Infors HT Microton, Bottmingen,
Switzerland). When cultures reached an OD600 of 0.4 –
0.6, PglB and EPA expression was induced by adding
1 mM IPTG and 2 g/L arabinose respectively. N-
acetylglucosamine was added simultaneously with IPTG
(similar to shake flask experiments). After overnight
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a multi-channel pipette to a new DWP and harvested by
centrifugation (1600 × g, 10 min, 4°C). Supernatant was
withdrawn with a multi-channel pipette and periplasmic
extracts were prepared as described below.
Bioreactor fermentations
Optimization studies of high-cell density cultures were
carried out in a 4-parallel bioreactor system (Infors HT,
Multifors 2, Bottmingen, Switzerland) with a total vessel
volume of 1 L. The composition of the complex medium
was the same as described in the shake flask section, ex-
cept that the initial carbon concentration was increased
to 25 g/L glycerol. MgSO4, trace element solution and
antibiotics were sterilized separately and added after
autoclaving. The feeding solution consisted of 33 g/L
yeast extract (Bacto yeast extract, BD, Le Pont de Claix,
France), 67 g/L soy peptone (soy peptone A3 SC,
Organotechnie, La Courneuve, France), 250 g/L glycerol,
10 mM MgSO4 and 10 ml/L trace element solution. The
initial batch culture was started by inoculation of 0.5 L
medium with an overnight seed culture to a final start-
ing OD600 of 0.05. The pH was adjusted to 7.00+/−0.05
by the addition of 25% H3PO4 and 4 M KOH. Dissolved
oxygen levels (DO2) were kept at 30% saturation by
automated-enriching of the inlet air with pure oxygen.
Bioreactors were stirred at 1000 rpm during the whole
bioprocess. Foam formation was inhibited by the manual
addition of the anti-foaming agent Antifoam 204
(Sigma-Aldrich, Buchs, Switzerland). PglB and EPA ex-
pression were induced by addition of 1 mM IPTG and
2 g/L arabinose, respectively. After induction, inducers
were also added to the feed solution (concentration in
feed: 1 mM IPTG, 2 g/L arabinose) to ensure their con-
stant concentrations in the culture broth. Cell growth was
monitored during the whole process by measuring the op-
tical density (OD) at 600 nm using a UV-visible spectro-
photometer (Genesys 6, ThermoSpectronic, Lausanne,
Switzerland). Culture samples were diluted with deionized
H2O until the final OD600 value was less than 0.4.
Preparation of periplasmic extracts
In order to determine the specific productivity of glyco-
protein production under altered conditions periplasmic
proteins were isolated by an osmotic shock method [66].
In brief, cells corresponding to 2 (or 10) OD600 units
were harvested by centrifugation at 6500 × g for 5 mi-
nutes and 4°C. Subsequently cell pellets were resus-
pended in 200 μl (or 1 ml) of chilled sucrose-lysozyme
buffer (30 mM Tris–HCl pH 8, 20% w/v sucrose, 1 mM
EDTA, 1 mg/ml lysozyme and complete protease inhibi-
tor mix (Roche, Basel, Switzerland)) to a final OD600 of
10 and incubated on ice for 30 minutes. Periplasmic pro-
teins were separated from cell debris and protoplasts bycentrifugation at 6500 × g for 10 minutes at 4°C, and
supernatant was withdrawn and stored at −20°C until
further analysis.
Enzyme-linked immunosorbent assay (ELISA)
For quantification of relative glycoconjugate yields in
periplasmic extracts a sandwich ELISA was applied in a
96-well format (F96 MaxiSorp, Nunc). As capture anti-
body, protein G purified goat-anti-EPA antiserum (US
Biological/Lucerna Chem AG, Lucerne, Switzerland) was
diluted with 1 × PBS to a final concentration of 10 μg/ml,
and microtiter plate wells were coated with 60 μl of
capture antibody solution at 4°C overnight. All subsequent
incubation steps were performed at room temperature.
After four washing steps with 300 μl washing buffer PBST
(1 × PBS, 0.05% Tween) separated by a 2 minutes incuba-
tion period under vigorous shaking using an automated
microplate washer (Wellwash Versa, Thermo-Scientific,
Zurich, Switzerland) wells were blocked for 2 h with
300 μl blocking solution (1 × PBS, 10% dry milk) followed
by another washing procedure as described above. Sub-
sequently, periplasmic extracts containing glycoproteins
were diluted with dilution buffer (1 × PBS, 1% dry milk)
to appropriate final dilutions of 1:100, 1:1000 or
1:10000, respectively, and 50 μl diluted periplasmic ex-
tracts were applied to ELISA plates and incubated for
1 h thereby allowing the antigen EPA to bind to the
capture antibody. Unbound EPA-2a and unbound,
unglycosylated EPA carrier protein were removed by
four washing cycles with 300 μl washing buffer per well.
Next 50 μl of a specific polyclonal antibody against the
S. flexneri 2a polysaccharide chain developed in rabbit
(rabbit-anti-2a; GVXN#92, GlycoVaxyn AG, Schlieren,
Switzerland) were added as a 1:10000 dilution in 1 ×
PBS + 1% dry milk to the wells. After a 1 h incubation,
plates were washed four times with washing buffer
PBST to remove residual anti-2a antibody and probed
for another hour with 50 μl of a 1:20000 dilution in 1 ×
PBS + 1% dry milk of the peroxidase-coupled detection
antibody (goat anti-rabbit IgG-HRP, Bio-Rad, Reinach,
Switzerland). Four final washing steps were performed
before ELISA signals were developed with 100 μl Ultra-
TMB-ELISA HRP substrate (Thermo-Scientific Pierce).
The color reaction was stopped by addition of 100 μl of
1 N H2SO4 per well, and absorbance was measured in a
96-well photometer (BioTek, Synergy Mx, Lucerne,
Switzerland) at 450 nm. The obtained A450 values
allowed the relative comparison of EPA-2a in periplas-
mic extracts on the same plate. The highest A450 value
was subsequently normalized to 1.
Western blot analysis
Periplasmic extracts (5 μl) were supplemented by equal
volumes of 2 × SDS-PAGE sample buffer (4% SDS, 20%
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blue, 0.125 M Tris HCl) and denatured at 95°C for 5 mi-
nutes. Samples were analyzed by 8% SDS-PAGE and
transferred on a nitrocellulose membrane using the iBlot
blotting system (Invitrogen, Carlsbad, USA). After block-
ing with 1 × PBS 10% milk for 1 h, membranes were
probed with either rabbit anti-EPA antiserum (Sigma-
Aldrich, Buchs, Switzerland) or rabbit anti-2a antiserum
(GVXN#92, GlycoVaxyn AG, Schlieren, Switzerland),
both applied as 1:20000 dilution in 1 × PBS 1% dry
milk for 1 h. Prior to ECL-based chemiluminescent de-
tection of EPA-2a glycoconjugates (ChemiDoc-It, UVP,
Upland, USA) the membranes were hybridized with a
peroxidase-coupled secondary antibody (goat anti-rabbit
IgG-HRP, Bio-Rad, Reinach, Switzerland, 1:20000 in 1 ×
PBS 1% dry milk).
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